ReviewO&G open2025
Rate of Postpartum Readmission for Hypertension After Prescribing Nifedipine Upon Hospital Discharge Compared With Labetalol: A Systematic Review.
Review in O&G open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hypertension-related morbidity after delivery discharge: A comparison of nifedipine versus labetalol.Pregnancy (Hoboken, N.J.) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo systematically review the literature to evaluate the rate of postpartum readmission for hypertension in individuals with hypertensive disorders of pregnancy discharged on nifedipine compared with those discharged on labetalol. DATA SOURCES: We explored EMBASE, MEDLINE, Web of Science, CINAHL, ClinicalTrials.gov, and CENTRAL for studies that compared the rate of postpartum readmission for hypertension in individuals with hypertensive disorders of pregnancy who were treated with nifedipine, compared with labetalol. METHODS OF STUDY SELECTION: Two reviewers separately identified studies, obtained data, and gauged study quality. The rate of postpartum readmission for hypertension was compared, and 95% CIs were estimated. TABULATION INTEGRATION AND
resultsThree retrospective cohort studies and two randomized controlled trials were identified, with 30,950 individuals with postpartum hypertension that required treatment with nifedipine, compared with labetalol. In these studies, 39.6% (12,212/30,950) were treated with nifedipine and 60.5% (18,738/30,950) were treated with labetalol. Studies evaluated individuals with readmission for postpartum hypertension who delivered from January 2006 to December 2022. Four studies were conducted in the United States, and one was conducted in Pakistan. The weighted portion in individuals with readmission for postpartum hypertension was 2.4% (95% CI, 1.5-3.5%) in the nifedipine group, compared with 6.5% (95% CI, 4.1-9.3%) in the labetalol group. Based on these five comparative studies, postpartum readmission for hypertension occurred less in individuals treated with nifedipine than in individuals treated with labetalol.
conclusionTreatment with nifedipine in individuals with hypertensive disorders of pregnancy is associated with lower rates of postpartum readmission for hypertension, compared with labetalol. SYSTEMATIC REVIEW REGISTRATION: PROSPERO: CRD42024526931.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.